{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Lord+Freyberg&max-ddpCreated=2018-11-13T21%3A55%3A31.447Z&min-questionFirstAnswered.=2018-11-20T15%3A31%3A59.637Z&AnswerDate=2018-11-27", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography+information+for+Lord+Freyberg&max-ddpCreated=2018-11-13T21%3A55%3A31.447Z&min-questionFirstAnswered.=2018-11-20T15%3A31%3A59.637Z&AnswerDate=2018-11-27", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Lord+Freyberg&max-ddpCreated=2018-11-13T21%3A55%3A31.447Z&min-questionFirstAnswered.=2018-11-20T15%3A31%3A59.637Z&AnswerDate=2018-11-27&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Lord+Freyberg&_page=0&max-ddpCreated=2018-11-13T21%3A55%3A31.447Z&min-questionFirstAnswered.=2018-11-20T15%3A31%3A59.637Z&AnswerDate=2018-11-27", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Lord+Freyberg&max-ddpCreated=2018-11-13T21%3A55%3A31.447Z&min-questionFirstAnswered.=2018-11-20T15%3A31%3A59.637Z&AnswerDate=2018-11-27", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Lord+Freyberg&max-ddpCreated=2018-11-13T21%3A55%3A31.447Z&min-questionFirstAnswered.=2018-11-20T15%3A31%3A59.637Z&AnswerDate=2018-11-27", "items" : [{"_about" : "http://data.parliament.uk/resources/1006667", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1006667/answer", "answerText" : {"_value" : "<p>The Information Commissioner\u2019s (ICO) guidance summarises the general issue of charging for re-use, but does not go into specific details beyond this.<\/p><p> <\/p><p>Regulation 19 of RPSI states that in the case of bodies subject to regulations 15 (3) (a) or (b), complaints about re-use charges are subject to recommendation only by the Information Commissioner and appeals against recommendations can lead to a binding decision at tribunal.<\/p><p> <\/p><p>Museums and galleries\u2019 charging falls under regulation 15 (3) (c), meaning that the usual redress route of a binding decision by the Information Commissioner applies.<\/p><p> <\/p><p>The ICO have confirmed they will be updating their guidance to make this clear.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4247", "label" : {"_value" : "Biography information for Lord Ashton of Hyde"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Ashton of Hyde"}
        , "dateOfAnswer" : {"_value" : "2018-11-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-26T12:11:06.673Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "10"}
      , "answeringDeptShortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "answeringDeptSortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Museums and Galleries: Copyright"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government, further to the Written Answer by Lord Ashton of Hyde on 12 November (HL11086), which stated that \"Complaints about charges for re-use by museums and galleries may be referred to the Information Commissioner for a binding decision\u201d, whether this is consistent with the Information Commissioner\u2019s Office (ICO)\u2019s Guide to RPSI, which states that it \u201ccan issue a decision notice, unless the complaint concerns charges above marginal cost, in which case we make a non-binding recommendation\u201d, and the ICO\u2019s Decision Notice FS50619465 of 4 April 2017, which states that it can \u201conly make recommendations in respect of any charges levied under the RPSI.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
      ], "uin" : "HL11447"}
    , {"_about" : "http://data.parliament.uk/resources/1006668", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1006668/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) recommends molecular testing for the following cancers:<\/p><p>- Acute myeloid leukaemia;<\/p><p>- Bladder;<\/p><p>- Brain;<\/p><p>- Breast;<\/p><p>- Chronic lymphocytic leukaemia;<\/p><p>- Chronic myeloid leukaemia;<\/p><p>- Colorectal;<\/p><p>- Non-small-cell lung cancer;<\/p><p>- Melanoma;<\/p><p>- Oesophago-gastric;<\/p><p>- Ovarian, fallopian tube and peritoneal;<\/p><p>- Pancreatic;<\/p><p>- Prostate;<\/p><p>- Upper aerodigestive tract; and<\/p><p>- Unknown primary origin.<\/p><p>NICE refers to the following companion diagnostic biomarkers in its guidance:<\/p><p>- c-Kit (CD117);<\/p><p>- HER2;<\/p><p>- KRAS;<\/p><p>- EGFR-TK;<\/p><p>- Philadelphia chromosome;<\/p><p>- BRAF V600;<\/p><p>- ALK;<\/p><p>- BRCA;<\/p><p>- p53;<\/p><p>- PD-L1;<\/p><p>- RAS;<\/p><p>- BCR-ABL1;<\/p><p>- FLT3;<\/p><p>- ROS1;<\/p><p>- BRCA1 (germline); and<\/p><p>- Somatostatin receptor-positive.<\/p><p> <\/p><p>Tests that are primarily used for diagnosis, monitoring or screening often provide prognostic information. Consequently, there are a large number of biomarkers, many of which are used in standard testing practice and so are not specifically referred to in NICE guidance. Multiple and combinations of biomarkers are often used to provide prognostic information and companies developing tests often create their own combinations.<\/p><p>As many tests look for multiple biomarkers for a single purpose and many tests in standard practice provide prognostic information, NICE is unable to provide categorical information on prognostic tests.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T15:29:48.607Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Screening"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government which cancers have been recommended by NICE for molecular testing; and of those cancers, for which biomarkers in relation to (1) prognostic tests, and (2) theranostic or treatment predictive tests.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
      ], "uin" : "HL11448"}
    , {"_about" : "http://data.parliament.uk/resources/1006669", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1006669/answer", "answerText" : {"_value" : "<p>NHS England does not hold this information.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "HL11450"}
        , {"_value" : "HL11451"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T15:48:20.66Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Screening"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government which NHS England trusts currently carry out cancer tests in compliance with NICE guidelines; and in relation to which cancers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
      ], "uin" : "HL11449"}
    , {"_about" : "http://data.parliament.uk/resources/1006670", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1006670/answer", "answerText" : {"_value" : "<p>NHS England does not hold this information.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "HL11449"}
        , {"_value" : "HL11451"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T15:48:20.707Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Screening"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government which NHS England trusts, if any, have secured funding to test for cancers clinically beyond the NICE guidelines, including through use of theranostic tests and somatic gene panels that can report back to patients within a clinically actionable time frame; and in relation to which cancers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
      ], "uin" : "HL11450"}
    , {"_about" : "http://data.parliament.uk/resources/1006671", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1006671/answer", "answerText" : {"_value" : "<p>NHS England does not hold this information.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "HL11449"}
        , {"_value" : "HL11450"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T15:48:20.737Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Screening"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the main reasons for non-compliance with NICE guidelines for testing for cancer by NHS England trusts.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
      ], "uin" : "HL11451"}
    , {"_about" : "http://data.parliament.uk/resources/1006672", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1006672/answer", "answerText" : {"_value" : "<p>In 2015, the Independent Cancer Taskforce Report highlighted limited access to molecular diagnostics across the National Health Service and limited use of technology to systematically identify patients with cancer and suggested that this has resulted in the NHS falling behind other countries in the delivery of high-quality, cost-effective cancer care.<\/p><p>To address this, building on the world leading 100,000 Genomes Project and the existing infrastructure, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The GMS will bring together existing clinical genetics services and the new genomic laboratory infrastructure to provide seamless service delivery for patients with rare and inherited disease and cancer.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T15:48:42.947Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cancer: Screening"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what progress they have made towards the Cancer Task Force\u2019s recommendation for a national molecular pathology service; and when they anticipate to implement this fully in relation to adult cancer diagnosis and care.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2593", "label" : {"_value" : "Biography information for Lord Freyberg"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Freyberg"}
      ], "uin" : "HL11452"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}